• Erik E Folch, Michael A Pritchett, Michael A Nead, Mark R Bowling, Septimiu D Murgu, William S Krimsky, Boris A Murillo, Gregory P LeMense, Douglas J Minnich, Sandeep Bansal, Blesilda Q Ellis, Amit K Mahajan, Thomas R Gildea, Rabih I Bechara, Eric Sztejman, Javier Flandes, Otis B Rickman, Sadia Benzaquen, D Kyle Hogarth, Philip A Linden, Momen M Wahidi, Jennifer S Mattingley, Kristin L Hood, Haiying Lin, Jennifer J Wolvers, Sandeep J Khandhar, and NAVIGATE Study Investigators.
• Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: efolch@mgh.harvard.edu.
• J Thorac Oncol. 2019 Mar 1; 14 (3): 445-458.

IntroductionElectromagnetic navigation bronchoscopy (ENB) is a minimally invasive technology that guides endoscopic tools to pulmonary lesions. ENB has been evaluated primarily in small, single-center studies; thus, the diagnostic yield in a generalizable setting is unknown.MethodsNAVIGATE is a prospective, multicenter, cohort study that evaluated ENB using the superDimension navigation system (Medtronic, Minneapolis, Minnesota). In this United States cohort analysis, 1215 consecutive subjects were enrolled at 29 academic and community sites from April 2015 to August 2016.ResultsThe median lesion size was 20.0 mm. Fluoroscopy was used in 91% of cases (lesions visible in 60%) and radial endobronchial ultrasound in 57%. The median ENB planning time was 5 minutes; the ENB-specific procedure time was 25 minutes. Among 1157 subjects undergoing ENB-guided biopsy, 94% (1092 of 1157) had navigation completed and tissue obtained. Follow-up was completed in 99% of subjects at 1 month and 80% at 12 months. The 12-month diagnostic yield was 73%. Pathology results of the ENB-aided tissue samples showed malignancy in 44% (484 of 1092). Sensitivity, specificity, positive predictive value, and negative predictive value for malignancy were 69%, 100%, 100%, and 56%, respectively. ENB-related Common Terminology Criteria for Adverse Events grade 2 or higher pneumothoraces (requiring admission or chest tube placement) occurred in 2.9%. The ENB-related Common Terminology Criteria for Adverse Events grade 2 or higher bronchopulmonary hemorrhage and grade 4 or higher respiratory failure rates were 1.5% and 0.7%, respectively.ConclusionsNAVIGATE shows that an ENB-aided diagnosis can be obtained in approximately three-quarters of evaluable patients across a generalizable cohort based on prospective 12-month follow-up in a pragmatic setting with a low procedural complication rate.Copyright © 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

22 keywords...

hide…